A.G. Schneiderman Announces Resolution Of Lawsuit That Protected Alzheimer's Patients From Anticompetitive Tactic Aimed At Maintaining Higher Drug Prices
NEW YORK - Attorney General Eric T. Schneiderman today announced that his office has resolved the antitrust lawsuit it brought in September 2014, which has successfully prevented pharmaceutical manufacturer Allergan plc (previously named Actavis plc) from forcing Alzheimer's patients to switch medications as part of an anticompetitive strategy designed to maintain high drug prices. In December 2014, a federal judge granted New York's request for an injunction and prohibited Allergan from engaging in the controversial tactic - sometimes called a "forced switch" - which would have needlessly disrupted the treatment plans of these patients solely to protect corporate profits. Because the injunction protected competition and allowed low cost generic drugs to enter the market unimpeded, the Attorney General's office has determined that it is no longer necessary to continue legal action.
- Date:November 25, 2015
- Agency:New York Attorney General
- State Enforcement Agencies